Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of RO6889678 in Healthy Subjects
NCT02321384Phase 1Terminated
- Sponsor
- Roche
- Start
- Dec 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RO6889678 in hepatitis B (HBV), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events up to 12 weeks, Maximum Observed Plasma Concentration at Day 14 and 11 more. Started Dec 2014; status: terminated.
02
Drugs
RO6889678
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02321384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321384.